OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Sungho HAN

1 Projects | 1 Researchers | $600,000 Invested

2023

Genuv Inc.

Sungho HAN

Preclinical study to explore the proof-of concept of trametinib at the lowest dose for the development of a disease-modifying treatment for Alzheimer’s disease

  • Funding Amount: $600,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuronal Regeneration and Repair
  • Status: Active